Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock

Parasitology

Volumn 141, Issue 12, 2014, Pages 1628-1637

  Caldas, Sérgio ^a,b   Caldas, Ivo Santana ^a,c   Cecílio, Alzira Batista ^b   Diniz, Lívia De Figueiredo ^a   Talvani, André ^a   Ribeiro, Isabela ^d   Bahia, Maria Terezinha ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^c FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^d Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

benznidazole; chemotherapy; fexinidazole; inflammation; posaconazole; real time PCR; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; FEXINIDAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; POSACONAZOLE; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CARDITIS; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; FEMALE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PARASITE LOAD; PARASITISM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TRYPANOSOMA CRUZI;

ANIMALIA; MUS; TRYPANOSOMA CRUZI;

EID: 84906794225     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182014000882     Document Type: Article

References (35)

1. Aliberti, J. C., Machado, F. S., Souto, J. T., Campanelli, A. P., Teixeira, M. M., Gazzinelli, R. T. and Silva, J. S. (1999). Betachemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infection and Immunity 67, 4819-4826.
2. Andrade, S. G., Stocker-Guerret, S., Pimentel, A. S. and Grimaud, J. A. (1991). Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Memórias do Insituto Oswaldo Cruz 86, 187-200.
3. Ãnez, N., Carrasco, H., Parada, H., Crisante, G., Rojas, A., Fuenmayor, C., Gonzales, N., Percoco, G., Borges, R., Guevara, P. and Ramirez, J. L. (1999). Myocardial parasite persistence in chronic chagasic patients. American Journal of Medicine and Tropical Hygiene 60, 726-732.
4. Bahia, M. T., de Andrade, I. M., Martins, T. A., Nascimento, A. F. S., Diniz, L. F., Caldas, I. S., Talvani, A., Trunz, B. B., Torreele, E. and Ribeiro, I. (2012). Fexinidazole: a potential new drug candidate for Chagas disease. PLOS Neglected Tropical Diseases 6, e1870.
5. Bahia, M., Nascimento, A. F., Mazzeti, A. L., Marques, L. F., Gonçalves, K. R., Mota, L.W., Diniz, L. F., Caldas, I. S., Talvani, A., Shackleford, D. M., Koltun, M., Saunders, J., White, K. L., Scandale, I., Charman, S. A. and Chatelain, E. (2014). Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease. Antimicrobial Agents and Chemotherapy. Epub ahead of print. doi: 10.1128/AAC.02754-13.
6. Brener, Z. (1962). Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Revista Instituto de Medicina Tropical de São Paulo 4, 389-396.
7. Caldas, I. S., Talvani, A., Caldas, S., Carneiro, C., de Lana, M., Guedes, P. M. M. and Bahia, M. T. (2008). Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitology Research 103, 413-421.
8. Caldas, S., Caldas, I. S., Diniz, L. F., Lima, W. G., Oliveira, R. de P., Cecílio, A. B., Ribeito, A., Talvani, A. and Bahia, M. T. (2012). Real-time PCR strategy for parasite quantification in blood and tissue samples of experimental Trypanosoma cruzi infection. Acta Tropica 123, 170-177.
9. Cançado, J. R. (2000). Long term evaluation of etiological treatment of Chagas disease with benznidazole. Revista do Instituto de Medicina Tropical de São Paulo 44, 29-37.
10. Cook, D. N., Smithies, O., Strieter, R. M., Frelinger, J. A. and Serody, J. S. (1999). CD8+ T cells are a biologically relevant source of macrophage inflammatory protein-1 alpha in vivo. Journal of Immunology 162, 5423-5428.
11. Cummings, K. L. and Tarleton, R. L. (2003). Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Molecular and Biochemical Parasitology 129, 53-59.
12. Diniz, L. F., Caldas, I. S., Guedes, P. M. M., Crepalde, G. P., de Lana, M., Carneiro, C. M., Talvani, A., Urbina, J. A. and Bahia, M. T. (2010). Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 54, 2979-2986.
13. Diniz, L. F., Urbina, J. A., de Andrade, I. M., Mazzetti, A. L., Martins, T. A. F., Caldas, I. S., Talvani, A., Ribeiro, I. and Bahia, M. T. (2013). Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLOS Neglected Tropical Diseases 7, e2367.
14. Docampo, R. and Moreno, S. N. J. (1986). Free-radical metabolism of antiparasitic agents. Federation Proceedings 45, 2471-2476.
15. Filardi, L. S. and Brener, Z. (1987). Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 755-759.
16. Garcia, S., Ramos, C. O., Senra, J. F., Vilas-Boas, F., Rodrigues, M. M., Campos-de-Carvalho, A. C., Ribeiro-Dos-Santos, R. and Soares, M. B. (2005). Treatment with benznidazole during the chronic phase of experimental Chagas disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 49, 1521-1528.
17. Guedes, P. M. M., Urbina, J. A., de Lana, M., Afonso, L. C., Veloso, V. M., Tafuri, W. L., Machado-Coelho, G. L., Chiari, E. and Bahia, M. T. (2004). Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrobial Agents and Chemotherapy 48, 4286-4292.
18. Hardison, J. L., Wrightsman, R. A., Carpenter, P. M., Kuziel, W. A., Lane, T. E. and Manning, J. E. (2006). The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi. Infection and Immunity 74, 135-143.
19. Hall, B. S. and Wilkinson, S. R. (2011). Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrobial Agents and Chemotherapy 56, 115-123.
20. Machado, F. S., Martins, G. A., Aliberti, J. C., Mestriner, F. L., Cunha, F. Q. and Silva, J. S. (2000). Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation 102, 3003-3008.
21. Machado, F. S., Souto, J. T., Rossi, M. A., Esper, L., Tanowitz, H. B., Aliberti, J. and Silva, J. S. (2008). Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes. Microbes and Infection 10, 1558-1566.
22. Molina, J., Martins-Filho, O., Brener, Z., Romanha, A. J., Loebenberg, D. and Urbina, J. A. (2000). Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrobial Agents and Chemotherapy 44, 150-155.
23. Paiva, C. N., Figueiredo, R. T., Kroll-Palhares, K., Silva, A. A., Silvério, J. C., Gibaldi, D., Pyrrho Ados, S., Benjamim, C. F., Lannes-Vieira, J. and Bozza, M. T. (2009). CCL2/MCP-1 controls parasite burden, cell infiltration, and mononuclear activation during acute Trypanosoma cruzi infection. Journal of Leukocyte Biology 86, 1239-1246.
24. Pinazo, M. J., Espinosa, G., Gállego, M., López-Chejade, P. L., Urbina, J. A. and Gascón, J. (2010). Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. American Journal of Tropical Medicine and Hygiene 82, 583-587.
25. Raether, W. and Seidenath, H. (1983). The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Annals of Tropical Medicine and Parasitology 77, 13-26.
26. Sallusto, F., Lanza Vecchia, A. and Mackay, C. R. (1998). Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunology Today 19, 568-574.
27. Santos, F. M., de Lima, W. G., Gravel, A., Martins, T. A., Talvani, A., Torres, R. M. and Bahia, M. T. (2012). Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease. Journal of Antimicrobial Chemotherapy 68, 1-9.
28. Sokolova, A. Y., Wyllie, S., Patterson, S., Oza, S. L., Read, K. D. and Fairlamb, A. H. (2010). Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrobial Agents and Chemotherapy 54, 2893-2900.
29. Talvani, A., Ribeiro, C. S. and Aliberti, J. C. S. (2000). Kinetics of cytokine genes expression in experimental chagasic cardiomyopathy: a direct correlation between levels of tissue parasitism and chemokine mRNAs expression during infection with Trypanosoma cruzi. Microbes and Infection 2, 851-866.
30. Tarleton, R. L. and Zhang, L. (1999). Chagas disease etiology: autoimmunity or parasite persistence? Parasitology Today 15, 94-99.
31. Tarleton, R. L., Sun, J., Zhang, L. and Postan, M. (1994). Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease. Infection and Immunity 62, 1820-1829.
32. Torreele, E., Trunz, B. B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., Bray, M. A. and Pécoul, B. (2010). Fexinidazole: a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLOS Neglected Tropical Diseases 4, e923.
33. Urbina, J. A. (2010). Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Tropica 115, 55-68.
34. Wilkinson, S. R. and Kelly, J. M. (2009). Trypanocidal drugs: mechanisms, resistance and new targets. Expert Reviews in Molecular Medicine 11, e31.
35. Workman, P., White, R. A., Walton, M. I., Owen, L. N. and Twentyman, P. R. (1979). Preclinical pharmacokinetics of benznidazole. British Journal of Cancer 50, 291-303.